Cargando…

Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults

BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoburg, Arnd, Löer, Ingo, Körsmeier, Konrad, Siebold, Rainer, Niemeyer, Philipp, Fickert, Stefan, Ruhnau, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484242/
https://www.ncbi.nlm.nih.gov/pubmed/31041335
http://dx.doi.org/10.1177/2325967119841077
_version_ 1783414082931523584
author Hoburg, Arnd
Löer, Ingo
Körsmeier, Konrad
Siebold, Rainer
Niemeyer, Philipp
Fickert, Stefan
Ruhnau, Klaus
author_facet Hoburg, Arnd
Löer, Ingo
Körsmeier, Konrad
Siebold, Rainer
Niemeyer, Philipp
Fickert, Stefan
Ruhnau, Klaus
author_sort Hoburg, Arnd
collection PubMed
description BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/Spherox) is an effective and safe treatment for articular cartilage defects in adolescents aged 15 to 17 years, with outcomes comparable with those for young adults aged 18 to 34 years. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A total of 71 patients (29 adolescents, 42 young adults) who had undergone ACI using spheroids were evaluated retrospectively in this multicenter study. For adolescents, the mean defect size was 4.6 ± 2.4 cm(2), and the follow-up range was 3.5 to 8.0 years (mean, 63.3 months). For young adults, the mean defect size was 4.7 ± 1.2 cm(2), and the follow-up range was 3.8 to 4.3 years (mean, 48.4 months). At the follow-up assessment, outcomes were assessed by using validated questionnaires (Knee injury and Osteoarthritis Outcome Score [KOOS], International Knee Documentation Committee [IKDC] subjective knee evaluation form and current health assessment form, and modified Lysholm score), the magnetic resonance observation of cartilage repair tissue (MOCART) score, and if relevant, time to treatment failure. Safety was assessed by the treatment failure rate. RESULTS: No significant difference between the 2 study groups was found for KOOS, IKDC, or MOCART scores, with all patients achieving high functional values. A significant difference was found in the modified Lysholm score, favoring the young adult group over the adolescent group (22.3 ± 1.9 vs 21.0 ± 2.4, respectively; P = .0123). There were no differences between the rates of treatment failure, with 3% in the adolescent group and 5% in the young adult group. CONCLUSION: Third-generation MACI using spheroids is a safe and effective treatment for large cartilage defects of the knee in adolescents at midterm follow-up. Outcomes are comparable with those for young adults after ACI.
format Online
Article
Text
id pubmed-6484242
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64842422019-04-30 Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults Hoburg, Arnd Löer, Ingo Körsmeier, Konrad Siebold, Rainer Niemeyer, Philipp Fickert, Stefan Ruhnau, Klaus Orthop J Sports Med Article BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/Spherox) is an effective and safe treatment for articular cartilage defects in adolescents aged 15 to 17 years, with outcomes comparable with those for young adults aged 18 to 34 years. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A total of 71 patients (29 adolescents, 42 young adults) who had undergone ACI using spheroids were evaluated retrospectively in this multicenter study. For adolescents, the mean defect size was 4.6 ± 2.4 cm(2), and the follow-up range was 3.5 to 8.0 years (mean, 63.3 months). For young adults, the mean defect size was 4.7 ± 1.2 cm(2), and the follow-up range was 3.8 to 4.3 years (mean, 48.4 months). At the follow-up assessment, outcomes were assessed by using validated questionnaires (Knee injury and Osteoarthritis Outcome Score [KOOS], International Knee Documentation Committee [IKDC] subjective knee evaluation form and current health assessment form, and modified Lysholm score), the magnetic resonance observation of cartilage repair tissue (MOCART) score, and if relevant, time to treatment failure. Safety was assessed by the treatment failure rate. RESULTS: No significant difference between the 2 study groups was found for KOOS, IKDC, or MOCART scores, with all patients achieving high functional values. A significant difference was found in the modified Lysholm score, favoring the young adult group over the adolescent group (22.3 ± 1.9 vs 21.0 ± 2.4, respectively; P = .0123). There were no differences between the rates of treatment failure, with 3% in the adolescent group and 5% in the young adult group. CONCLUSION: Third-generation MACI using spheroids is a safe and effective treatment for large cartilage defects of the knee in adolescents at midterm follow-up. Outcomes are comparable with those for young adults after ACI. SAGE Publications 2019-04-25 /pmc/articles/PMC6484242/ /pubmed/31041335 http://dx.doi.org/10.1177/2325967119841077 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Hoburg, Arnd
Löer, Ingo
Körsmeier, Konrad
Siebold, Rainer
Niemeyer, Philipp
Fickert, Stefan
Ruhnau, Klaus
Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title_full Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title_fullStr Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title_full_unstemmed Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title_short Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
title_sort matrix-associated autologous chondrocyte implantation is an effective treatment at midterm follow-up in adolescents and young adults
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484242/
https://www.ncbi.nlm.nih.gov/pubmed/31041335
http://dx.doi.org/10.1177/2325967119841077
work_keys_str_mv AT hoburgarnd matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT loeringo matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT korsmeierkonrad matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT sieboldrainer matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT niemeyerphilipp matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT fickertstefan matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults
AT ruhnauklaus matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults